IN2012DN03817A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN03817A IN2012DN03817A IN3817DEN2012A IN2012DN03817A IN 2012DN03817 A IN2012DN03817 A IN 2012DN03817A IN 3817DEN2012 A IN3817DEN2012 A IN 3817DEN2012A IN 2012DN03817 A IN2012DN03817 A IN 2012DN03817A
- Authority
- IN
- India
- Prior art keywords
- treatment
- biomarkers
- inhibitor
- proliferative
- predict
- Prior art date
Links
- 229940122360 Casein kinase 2 inhibitor Drugs 0.000 abstract 2
- 239000000090 biomarker Substances 0.000 abstract 2
- 102000043139 CK2 family Human genes 0.000 abstract 1
- 102000052052 Casein Kinase II Human genes 0.000 abstract 1
- 108010010919 Casein Kinase II Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 230000035945 sensitivity Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
- G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24827009P | 2009-10-02 | 2009-10-02 | |
| US25580509P | 2009-10-28 | 2009-10-28 | |
| US32377110P | 2010-04-13 | 2010-04-13 | |
| US38068510P | 2010-09-07 | 2010-09-07 | |
| PCT/US2010/051341 WO2011041785A1 (en) | 2009-10-02 | 2010-10-04 | Biomarkers for predicting the sensitivity and response of protein kinase ck2-mediated diseases to ck2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN03817A true IN2012DN03817A (enExample) | 2015-08-28 |
Family
ID=43128291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3817DEN2012 IN2012DN03817A (enExample) | 2009-10-02 | 2010-10-04 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20110212845A1 (enExample) |
| EP (1) | EP2483686A1 (enExample) |
| JP (1) | JP2013506836A (enExample) |
| KR (1) | KR20120104196A (enExample) |
| AU (1) | AU2010300307A1 (enExample) |
| BR (1) | BR112012007555B1 (enExample) |
| CA (1) | CA2776278A1 (enExample) |
| IL (1) | IL218935A0 (enExample) |
| IN (1) | IN2012DN03817A (enExample) |
| MX (1) | MX2012003997A (enExample) |
| WO (1) | WO2011041785A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201212773D0 (en) * | 2012-07-18 | 2012-08-29 | Ucl Business Plc | Vascular remodelling |
| US9146545B2 (en) | 2012-11-27 | 2015-09-29 | Honeywell International Inc. | Multivariable control system for setpoint design |
| TWI582239B (zh) | 2013-03-11 | 2017-05-11 | 諾華公司 | 與ｗｎｔ抑制劑相關之標記 |
| WO2015053452A1 (ko) * | 2013-10-08 | 2015-04-16 | 한국생명공학연구원 | Ｃｘ－４９４５를 유효성분으로 함유하는 스플라이싱 조절제 |
| KR101593595B1 (ko) * | 2013-10-08 | 2016-02-12 | 한국생명공학연구원 | Ｃｘ－４９４５를 유효성분으로 함유하는 스플라이싱 조절제 |
| DK3108255T3 (da) * | 2014-02-18 | 2020-11-09 | Inst Nat Sante Rech Med | Fremgangsmåder og farmaceutiske sammensætninger til behandling af sygdomme medieret af nrp-1/obr-komplekssignalvejen |
| SI3170005T1 (sl) * | 2014-07-18 | 2019-08-30 | Sanofi | Postopek napovedovanja izida zdravljenja z afliberceptom, pacienta, pri katerem obstaja sum, da je zbolel za rakom |
| WO2016133860A1 (en) * | 2015-02-16 | 2016-08-25 | Board Of Regents Of The University Of Nebraska | Cancer biomarkers and methods of use thereof |
| GB202102895D0 (en) * | 2021-03-01 | 2021-04-14 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
| EP4403581A4 (en) * | 2022-03-30 | 2025-06-18 | Miwako Homma | ANTI-CK2 ALPHA ANTIBODY OR FRAGMENT THEREOF |
| CN115160341B (zh) * | 2022-07-18 | 2023-07-18 | 中国医学科学院医学实验动物研究所 | 苯并噁嗪类化合物及其药物用途 |
| KR102641010B1 (ko) * | 2023-12-04 | 2024-02-28 | 대한민국 | 실미타세르팁을 유효성분으로 포함하는 중증열성혈소판감소증후군 예방 또는 치료용 약학 조성물 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200715636A (en) | 2005-10-04 | 2007-04-16 | Antig Tech Co Ltd | Method of controlling fuel concentration used in direct liquid fuel cell |
| US7956064B2 (en) | 2006-09-01 | 2011-06-07 | Cylene Pharmaceuticals, Inc. | Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators |
| US8488289B2 (en) | 2006-09-27 | 2013-07-16 | International Rectifier Corporation | Current protection circuit for intelligent power switch |
| US20090035609A1 (en) | 2007-07-31 | 2009-02-05 | Apple Inc. | Intelligent universal rechargeable batteries for battery charging system for mobile and accessory devices |
-
2010
- 2010-10-04 US US12/897,640 patent/US20110212845A1/en not_active Abandoned
- 2010-10-04 MX MX2012003997A patent/MX2012003997A/es not_active Application Discontinuation
- 2010-10-04 CA CA2776278A patent/CA2776278A1/en not_active Abandoned
- 2010-10-04 AU AU2010300307A patent/AU2010300307A1/en not_active Abandoned
- 2010-10-04 BR BR112012007555-1A patent/BR112012007555B1/pt active IP Right Grant
- 2010-10-04 WO PCT/US2010/051341 patent/WO2011041785A1/en not_active Ceased
- 2010-10-04 EP EP10765546A patent/EP2483686A1/en not_active Withdrawn
- 2010-10-04 JP JP2012532136A patent/JP2013506836A/ja active Pending
- 2010-10-04 IN IN3817DEN2012 patent/IN2012DN03817A/en unknown
- 2010-10-04 KR KR1020127011401A patent/KR20120104196A/ko not_active Withdrawn
-
2012
- 2012-03-29 IL IL218935A patent/IL218935A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20110212845A1 (en) | 2011-09-01 |
| CA2776278A1 (en) | 2011-04-07 |
| IL218935A0 (en) | 2012-07-31 |
| WO2011041785A1 (en) | 2011-04-07 |
| MX2012003997A (es) | 2012-07-25 |
| EP2483686A1 (en) | 2012-08-08 |
| BR112012007555A2 (pt) | 2016-10-25 |
| BR112012007555B1 (pt) | 2020-09-29 |
| JP2013506836A (ja) | 2013-02-28 |
| KR20120104196A (ko) | 2012-09-20 |
| AU2010300307A1 (en) | 2012-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN03817A (enExample) | ||
| MX356802B (es) | Marcadores biologicos para identificar pacientes para tratamiento con antagonistas de vegf. | |
| WO2015031808A3 (en) | Diagnostic methods and compositions for treatment of glioblastoma | |
| GB2463401B (en) | Characterizing prostate disorders by analysis of microvesicles | |
| EP4349248A3 (en) | Apparatus for determining damaged tissue using sub-epidermal moisture measurements | |
| MX2010006854A (es) | Biomarcadores para sensibilidad a terapia anti-receptor-1 del factor de crecimiento tipo insulina. | |
| MX2012009030A (es) | Identificacion de mutacion lkb1 como biomarcador predictivo para sensibilidad a inhibidores de tor cinasa. | |
| HK1208470A1 (en) | Biomarkers for use in integrin therapy applications | |
| BR112013030606A2 (pt) | biomarcadores para terapia inibidora de hedgehog | |
| DK1846424T3 (da) | Proteasom-inhibitorer og fremgangsmåder til anvendelse deraf | |
| MX2014001246A (es) | Identificación del perfil de la expresión génica como biomarcador predictivo del estatus de lkb1. | |
| MX358517B (es) | Métodos para determinar eficacia de fármacos usando proteínas asociadas a cereblon. | |
| MX2019005443A (es) | Combinacion de un inhibidor de brd4 y un antifolato para la terapia del cancer. | |
| NZ630026A (en) | Inhibition of the glycine cleavage system for treatment of cancer | |
| CO6680668A2 (es) | Ensayos biomarcadores para detectar o medir inhibición de actividad quinasa tor | |
| NZ584787A (en) | Inhibition of angiogenesis with a Bv8 antagonist | |
| MX2016007066A (es) | Identificacion de marcadores biologicos predictivos asociados con inhibidores de la via de wnt. | |
| TR201907241T4 (tr) | IL-17 inhibitörü terapisi etkinliği için bir biyo-işaret olarak lipokalin 2. | |
| PH12019501942A1 (en) | Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor | |
| GB2480980A (en) | Methods for predicting cancer response to EGFR inhibitors | |
| MX384423B (es) | Biomarcadores para la respuesta a inhibidores del mejorador del homólogo 2 de zeste (ezh2). | |
| NZ738389A (en) | Inhibitor of igfbp3/tmem219 axis and diabetes | |
| WO2012068464A3 (en) | Methods of treating and preventing thrombotic diseases using ask1 inhibitors | |
| WO2015049390A3 (en) | Kidney disease biomarker | |
| MX2012001999A (es) | Uso de inhibidores nkg2d para tratar enfermedades cardiovasculares y metabolicas, tal como diabetes tipo 2. |